Emerging nations 'will push drug spending above $1trn'
Wednesday 21 April 2010
Global spending on pharmaceuticals is expected to break through the $1trillion (£650bn) barrier over the next five years as demand from emerging economies surges, research shows.
Drug sales are expected to grow at between 5 and 8 per cent per year until 2014, taking the total spent to $1.1trn, according to IMS Health, a healthcare industry intelligence group.
Established drugs losing their patent protection in the developing world, combined with stronger demand from these countries, will push up sales by nearly $300bn a year, the group said.
"Patient demand for pharmaceuticals will remain robust, despite the ongoing effects of the downturn being felt in many parts of the world," said Murray Aitken, a senior vice-president at IMS Health. "In developed markets with publicly funding healthcare plans, pressure by payers to curb drug spending will only intensify, but that will be more than offset by the ongoing, rapid expansion of demand in the emerging markets".
IMS expects drug sales in developing nations to grow at between 14 and 17 per cent over the next five years, overshadowing Western markets that will expand at between just 3 and 6 per cent. Despite this surge in emerging economies, IMS Health predicts that the US will continue to be the world's biggest market for healthcare, with a spend of $390bn by 2014.
Forecasts of stronger growth will come as welcome relief to the giants of the pharmaceuticals industry. Companies such as GlaxoSmithKline and AstraZeneca have reported stiffer competition in recent years from makers of generic drugs, who increasingly have used the courts to challenge the patents owned by the majors.
By 2014, drugs whose sales currently total $142bn will face new competition from cheaper generics, according to IMS. In the US, six blockbuster drugs will lose their patent protection by 2012, including GSK's asthma treatment, Advair, and Pfizer's anti-cholesterol pill, Lipitor. GSK and AstraZeneca have ramped up their efforts in emerging markets. David Brennan, the chief executive of AstraZeneca, said recently: "There is no denying the scale of the opportunity these markets present but, like anything else in this industry, it takes a sound strategy and excellent execution." Yesterday, the company said: "Everyone points to population growth in emerging markets, but what is as important is the rising demand driven by increasing middle classes."
Despite the predictions of strong growth, 2010 will see a temporary slowdown. The global market is expected to expand by between 4 and 6 per cent this year – compared with 7 per cent growth last year, when the market was worth $837bn. In 2008, the industry grew by 4.8 per cent.
IMS Health said this year's falls would be triggered by tighter price controls imposed by European governments. It also predicted that certain therapy areas were likely to lead international growth. Its report added: "As pharmaceutical industry research and development programmes adjust to the broad availability of low-cost generic options in many chronic therapy areas, higher growth will occur in those therapy areas where there is significant, unmet clinical need."
- 2 Why this father didn’t hide his daughter’s heroin overdose in her obituary
- 3 Company breaks open Apple Watch to discover what it says is 'planned obsolescence'
- 5 The most powerful passports in the world
Nepal earthquake in pictures: Photos show devastation caused by 7.8 magnitude earthquake
Smartphones are making children borderline autistic, says psychiatrist
Nepal earthquake: The race is on to help thousands trapped under rubble around Kathmandu, while remote villages face a long wait for help
Royal baby: Live updates as superbug closes ward at St Mary's Hospital where Duchess of Cambridge is due to give birth
Teaching profession headed for crisis as numbers continue to drop and working lives become 'unbearable'
General Election 2015: Chuka Umunna on the benefits of immigration, humility – and his leader Ed Miliband
The sickening truth about food banks that the Tories don't want you to know
Migrant boat disaster: Ukip candidate mocks victims in sickening Twitter post
Nigel Farage wants the BBC to stop making programmes like Doctor Who, Strictly Come Dancing, and Top Gear
Global warming: Scientists say temperatures could rise by 6C by 2100 and call for action ahead of UN meeting in Paris
General Election 2015: Britain would become a 'communist dictatorship' under Ed Miliband and Nicola Sturgeon, claims wife of Michael Gove
iJobs Money & Business
£24000 - £26000 per annum + benefits : Ashdown Group: A highly successful, glo...
£50000 - £55000 per annum: Ashdown Group: Business Analyst - Financial Service...
£18000 - £23000 per annum + OTE £45K: SThree: At SThree, we like to be differe...
£20000 - £25000 per annum + competitive: SThree: Did you know? SThree is the o...